About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Sun Pharmaceutical Industries Ltd.
Change Company
BSE Code
524715
ISIN Demat
INE044A01036
Book Value
103.25
NSE Code
SUNPHARMA
Dividend Yield %
0.74
Market Cap
4363790.48
P/E
138.54
EPS
13.13
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
24-Apr-2025
Sun Pharmaceutical Industries informs about press...
14-Apr-2025
Sun Pharmaceutical Industries’ arm recalls around...
11-Apr-2025
US court lifts restrictions on Sun Pharma launchi...
11-Apr-2025
Sun Pharma surges after US court lifts restrictio...
07-Apr-2025
Sun Pharma launches Fexuprazan tablets 40 mg in I...
07-Apr-2025
Sun Pharmaceutical Industries informs about press...
02-Apr-2025
Sun Pharmaceutical Industries informs about chang...
18-Mar-2025
Sun Pharmaceutical Industries’ arm acquires Antib...
17-Mar-2025
Sun Pharma’s arm recalls 9,840 bottles of Morphin...
10-Mar-2025
Sun Pharma to acquire Checkpoint Therapeutics
10-Mar-2025
Sun Pharma rises on plans to acquire Checkpoint T...
10-Mar-2025
Sun Pharmaceutical Industries informs about press...
18-Feb-2025
Sun Pharmaceutical Industries rises on the BSE
17-Feb-2025
Sun Pharmaceutical included in S&P Global Sustain...
17-Feb-2025
Sun Pharmaceutical Industries informs about press...
Page
1
of
3
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.